• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Research Update: Ratings On Swiss Cantons Of Graubuenden, Lucerne, And Schwyz Converted To Unsolicited Dec 11

  • ID: 2034676
  • December 2011
  • Region: Switzerland
  • Standard & Poors

FEATURED COMPANIES

  • Graubuenden (Canton of)
  • Graubuendner Kantonalbank
  • Lucerne (Canton of)
  • Luzerner Kantonalbank
  • Schwyz (Canton of)
  • Schwyzer Kantonalbank
  • MORE

Abstract
Standard & Poor's is converting its issuer credit ratings on the Swiss cantons of Graubuenden, Lucerne, and Schwyz to "unsolicited" in line with EU regulations. The ratings on the cantons serve as a component of the ratings on Graubuendner Kantonalbank, Luzerner Kantonalbank, and Schwyzer Kantonalbank, which remain solicited. On Dec. 19, 2011, Standard & Poor's Ratings Services converted its issuer credit ratings on the Swiss cantons of Graubuenden (AA+/Stable/A-1+), Lucerne (AA+/Stable/A-1+), and Schwyz (AAA/Stable/A-1+) to "unsolicited". We are converting the ratings in line with EU regulations as we do not have rating agreements with the three cantons. Article 10 of EU Regulation 1060/2009, which addresses matters relating to the disclosure and presentation of credit ratings, requires, among other things, that...

Companies mentioned in this report are:
- Graubuenden (Canton of)
- Schwyzer Kantonalbank
- Schwyz (Canton of)
- Graubuendner Kantonalbank
- Luzerner Kantonalbank
- Lucerne (Canton of)

Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial READ MORE >

Note: Product cover images may vary from those shown

- Graubuenden (Canton of)
- Schwyzer Kantonalbank
- Schwyz (Canton of)
- Graubuendner Kantonalbank
- Luzerner Kantonalbank
- Lucerne (Canton of)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Fluidigm Corporation Apple, Inc. CEVA Santé Animale Abbott Laboratories Ltd. Merck Group Allergan Inc. Pfizer, Inc.